PHARMAENGINE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.9 TWD | +2.94% |
|
+4.93% | -7.20% |
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 38.35 times its estimated earnings per share for the ongoing year.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -7.20% | 425M | - | ||
| +33.63% | 50.85B | B- | ||
| -0.09% | 42.82B | B | ||
| +49.62% | 42.03B | A | ||
| -4.96% | 29.55B | C | ||
| +11.18% | 26.11B | B- | ||
| -21.95% | 19.13B | B | ||
| +8.61% | 13.05B | B+ | ||
| +28.31% | 12.16B | C+ | ||
| +24.73% | 12.08B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 4162 Stock
- Ratings PharmaEngine, Inc.
